GIGYF2 anticorps (AA 350-500)
Aperçu rapide pour GIGYF2 anticorps (AA 350-500) (ABIN6141083)
Antigène
Voir toutes GIGYF2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 350-500
-
Séquence
- VDEGEECSDS EGSHNEEAKE PDKTNKKEGE KTDRVGVASE ETPQTSSSSA RPGTPSDHQS QEASQFERKD EPKTEQTEKA EEETRMENSL PAKVPSRGDE MVADVQQPLS QIPSDTASPL LILPPPVPNP SPTLRPVETP VVGAPGMGSV S
-
Réactivité croisée
- Humain, Souris, Rat
-
Attributs du produit
- Polyclonal Antibodies
-
Purification
- Affinity purification
-
Immunogène
- Recombinant fusion protein containing a sequence corresponding to amino acids 350-500 of human GIGYF2 (NP_001096617.1).
-
Isotype
- IgG
-
-
-
-
Indications d'application
- WB,1:500 - 1:1000,IHC,1:50 - 1:100
-
Commentaires
-
HIGH QUALITY
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- GIGYF2 (GRB10 Interacting GYF Protein 2 (GIGYF2))
-
Autre désignation
- GIGYF2
-
Sujet
- This gene contains CAG trinucleotide repeats and encodes a protein containing several stretches of polyglutamine residues. The encoded protein may be involved in the regulation of tyrosine kinase receptor signaling. This gene is located in a chromosomal region that was genetically linked to Parkinson disease type 11, and mutations in this gene were thought to be causative for this disease. However, more recent studies in different populations have been unable to replicate this association. Alternative splicing results in multiple transcript variants.,GIGYF2,GYF2,PARK11,PERQ2,PERQ3,TNRC15,Neuroscience,Neurodegenerative Diseases,Dopamine Signaling in Parkinson's Disease,GIGYF2
-
Poids moléculaire
- 148 kDa/149 kDa/150 kDa/152 kDa
-
ID gène
- 26058
-
UniProt
- Q6Y7W6
-
Pathways
- Feeding Behaviour, SARS-CoV-2 Protein Interactome
Antigène
-